Value sales of analgesics in France continue to record solid growth in 2023 following a dynamic performance the previous year. The key growth driver is the increasing demand for acetaminophen, with the brand Doliprane from Sanofi, convincingly leading value sales in both paediatric and adult segments. Acetaminophen plays a key role in driving the category's growth, with increasing demand emerging from the notable surge in viruses and illness in France.
The analyst's Analgesics in France report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2018-2022, allowing you to identify the sectors driving growth. Forecasts to 2027 illustrate how the market is set to change.
Product coverage:
Systemic Analgesics, Topical Analgesics/Anaesthetic.
Data coverage:
Market sizes (historic and forecasts), company shares, brand shares and distribution data.
The analyst's Analgesics in France report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2018-2022, allowing you to identify the sectors driving growth. Forecasts to 2027 illustrate how the market is set to change.
Product coverage:
Systemic Analgesics, Topical Analgesics/Anaesthetic.
Data coverage:
Market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
- Get a detailed picture of the Analgesics market;
- Pinpoint growth sectors and identify factors driving change;
- Understand the competitive environment, the market’s major players and leading brands;
- Use five-year forecasts to assess how the market is predicted to develop.
Table of Contents
ANALGESICS IN FRANCEKEY DATA FINDINGSCONSUMER HEALTH IN FRANCEDISCLAIMERDEFINITIONS
2023 DEVELOPMENTS
PROSPECTS AND OPPORTUNITIES
CATEGORY DATA
EXECUTIVE SUMMARY
MARKET INDICATORS
MARKET DATA
APPENDIX
SOURCES
